UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 167

Sortiert nach

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)

Annals of oncology, 2015-06, Vol.26 (6), p.1123-1128

2015

Volltextzugriff (PDF)

Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d′Étude des Tumeurs Uro-Génitales) study

European journal of cancer (1990), 2024-03, Vol.199, p.113534-113534, Article 113534

2024

Volltextzugriff (PDF)

A PET-based nomogram for oropharyngeal cancers

European journal of cancer (1990), 2017-04, Vol.75, p.222-230

2017

Volltextzugriff (PDF)

Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial

Annals of oncology, 2018-10, Vol.29, p.viii306-viii306

2018

Volltextzugriff (PDF)

Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up

Annals of oncology, 2018-10, Vol.29, p.viii271-viii271

2018

Volltextzugriff (PDF)

A Nomogram to predict parotid gland overdose in head and neck IMRT

Radiation oncology (London, England), 2016-06, Vol.11 (1), p.79-79, Article 79

2016

Volltextzugriff (PDF)

PO-164: PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic salivary gland carcinoma

Radiotherapy and oncology, 2015-02, Vol.114, p.76-77

2015

Volltextzugriff (PDF)

2601 Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma

European journal of cancer (1990), 2015-09, Vol.51, p.S511-S512

2015

Volltextzugriff (PDF)

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

The New England journal of medicine, 2018-08, Vol.379 (5), p.417-427

2018

Volltextzugriff (PDF)

Metastatic clear-cell renal cell carcinoma: Computed tomography texture analysis as predictive biomarkers of survival in patients treated with Nivolumab: NivoMics 01-Study

European urology open science (Online), 2020-07, Vol.19, p.e1103-e1104

2020

Volltextzugriff (PDF)

Randomized phase III trial of dose-dense MVAC or GC as perioperative chemotherapy for muscle-invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses

European urology open science (Online), 2020-07, Vol.19, p.e108-e109

2020

Volltextzugriff (PDF)

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)

European urology open science (Online), 2020-07, Vol.19, p.e871-e872

2020

Volltextzugriff (PDF)

KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)

European urology open science (Online), 2020-07, Vol.19, p.e875-e876

2020

Volltextzugriff (PDF)

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results

European urology open science (Online), 2020-07, Vol.19, p.e873-e874

2020

Volltextzugriff (PDF)

PO-0881: Anatomical markers of parotid overdosage during IMRT for locally advanced H&N guiding an adaptive RT strategy

Radiotherapy and oncology, 2014, Vol.111, p.S96-S96

2014

Volltextzugriff (PDF)

Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO)

Critical reviews in oncology/hematology, 2010-10, Vol.76 (1), p.71-78

2010

Volltextzugriff (PDF)

7143 POSTER Prognosis of Patients With Metastatic Renal Cell Carcinoma (mRCC) With Primary Resistance to Sunitinib: Is There Any Active Treatment?

European journal of cancer (1990), 2011, Vol.47, p.S518-S518

2011

Volltextzugriff (PDF)

2362MO Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study

Annals of oncology, 2023-10, Vol.34, p.S1201-S1201

2023

Volltextzugriff (PDF)

Intérêt de la surveillance scannographique après cystectomie pour cancer

Progrès en urologie (Paris), 2014-11, Vol.24 (13), p.808-808

2014

Volltextzugriff (PDF)

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

The Lancet (British edition), 2019-06, Vol.393 (10191), p.2591-2598

2019

Volltextzugriff (PDF)

Sunitinib en rechallenge dans le cancer du rein métastatique–Résultats de l’étude RESUME

Progrès en urologie (Paris), 2014-11, Vol.24 (13), p.821-821

2014

Volltextzugriff (PDF)

The neutrophil gelatinase-associated lipocalin, or LCN 2, marker of aggressiveness in clear cell renal cell carcinoma

Progrès en urologie (Paris), 2011-11, Vol.21 (12), p.851-858

2011

Volltextzugriff (PDF)

652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial

Annals of oncology, 2021-09, Vol.32, p.S678-S678

2021

Volltextzugriff (PDF)

Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma

Journal of clinical oncology, 2017-01, Vol.35 (2), p.194-200

2017

Volltextzugriff (PDF)

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Annals of oncology, 2024-01, Vol.35 (1), p.107-117

2024

Volltextzugriff (PDF)

1 – 25 von 167

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(142)
Mit Volltextzugriff
(148)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(53)
Life Sciences & Biomedicine
(46)
Humans
(35)
Female
(21)
Male
(20)
Aged
(18)
Middle Aged
(18)
Life Sciences
(16)
Oncology
(15)
Animals
(13)
Biological And Medical Sciences
(12)
Adult
(11)
Dogs
(10)
Prognosis
(9)
Chemotherapy
(8)
Surgery
(8)
Treatment Outcome
(8)
Chemistry
(7)
Exact Sciences And Technology
(7)
Hematology, Oncology And Palliative Medicine
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)

Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d′Étude des Tumeurs Uro-Génitales) study

A PET-based nomogram for oropharyngeal cancers

Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial

Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up

A Nomogram to predict parotid gland overdose in head and neck IMRT

PO-164: PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic salivary gland carcinoma

2601 Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

Metastatic clear-cell renal cell carcinoma: Computed tomography texture analysis as predictive biomarkers of survival in patients treated with Nivolumab: NivoMics 01-Study

Randomized phase III trial of dose-dense MVAC or GC as perioperative chemotherapy for muscle-invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)

KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results

PO-0881: Anatomical markers of parotid overdosage during IMRT for locally advanced H&N guiding an adaptive RT strategy

Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO)

7143 POSTER Prognosis of Patients With Metastatic Renal Cell Carcinoma (mRCC) With Primary Resistance to Sunitinib: Is There Any Active Treatment?

2362MO Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study

Intérêt de la surveillance scannographique après cystectomie pour cancer

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Sunitinib en rechallenge dans le cancer du rein métastatique–Résultats de l’étude RESUME

The neutrophil gelatinase-associated lipocalin, or LCN 2, marker of aggressiveness in clear cell renal cell carcinoma

652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial

Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Aktive Filter

Suchergebnisse filtern